Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.
We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.
We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.
Learn more about our Cardio Analysis Services
Experts in cardiac safety
Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.
Dr Ulrike Lorch joins the leadership team at the Faculty of Human Pharmacology
3
November 2021
Richmond Pharmacology’s Medical Director, Dr Ulrike Lorch, has been appointed Director of Human Pharmacology for the Faculty of Pharmaceutical Management (FPM).
Developing talent in the fast-changing clinical research environment
2
November 2021
In a feature article for PharmaTimes, Dr. Ulrike Lorch, Medical Director at Richmond Pharmacology, outlines how investing in the clinical research workforce is crucial to delivering high quality, cutting-edge trials and achieving faster drug development
Focal epilepsy treatment progresses following positive Phase IIb results
26
October 2021
Richmond Pharmacology’s research partner, Xenon Pharmaceuticals reported positive top line results from its Phase IIb X-TOLE clinical trial of XEN1101 – a differentiated Kv7 potassium channel modulator.
The future of new medicine development and first-in-human studies
26
October 2021
Dr Jorg Taubel outlines the future of new medicine development, influenced by the emergence of gene based therapies and reshaping first-in-human study design.
Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director
July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
